Crispr Therapeutics shares tumble after significant earnings miss
IRIDEX Corp (IRIX), a global leader in developing innovative and versatile laser-based medical systems, instruments, and devices for the ophthalmology market, has seen its stock price touch a 52-week low, reaching $1.27. According to InvestingPro data, the company’s financial health score is rated as ’FAIR’, with revenue of $48.4M in the last twelve months and a concerning EBITDA of -$10.1M. This price level reflects a significant downturn for the company, which has experienced a 1-year change with a decline of nearly 49.81%. The drop to the 52-week low underscores the challenges faced by the company in a competitive market, with a concerning gross profit margin of 38.8% and rapid cash burn rate. InvestingPro analysis reveals the stock is currently trading below its Fair Value, though analysts don’t expect profitability this year. For deeper insights into IRIDEX’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, covering over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Iridex Corporation has released its preliminary unaudited financial results for the fourth quarter and full year ending December 28, 2024. The company expects its fourth-quarter revenue to range between $12.6 million and $12.7 million, showing a slight increase from $12.5 million in the same quarter of the previous year. However, the annual revenue is anticipated to decline to between $48.6 million and $48.7 million, down from $51.9 million in 2023. Iridex reported the sale of 47 Cyclo G6® Glaucoma Laser Systems in the fourth quarter, an increase from 35 units sold in the same period last year. Meanwhile, the total number of Cyclo G6® probes sold in 2024 remained nearly unchanged at 54,800 compared to 55,200 in the previous year. CEO Patrick Mercer (NASDAQ:MERC) highlighted the company’s efforts towards achieving positive EBITDA results in the fourth quarter of 2024 and emphasized the focus on profitability in 2025. Additionally, Mercer mentioned ongoing discussions with multiple parties regarding potential transactions as part of a strategic review to enhance shareholder value. The preliminary results are subject to completion of year-end financial reporting processes, internal review, and external audit.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.